DURECT Corporation (DRRX) News

DURECT Corporation (DRRX): $1.51

0.02 (+1.34%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add DRRX to Watchlist
Sign Up

Filter DRRX News Items

DRRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest DRRX News From Around the Web

Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Q3 2023 DURECT Corp Earnings Call

Q3 2023 DURECT Corp Earnings Call

Yahoo | November 14, 2023

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update.

Yahoo | November 13, 2023

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 13, 2023

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call and webcast with investors to discuss financial results and provide a corpor

Yahoo | November 9, 2023

Cantor Fitzgerald Is Souring on Lucid Motors (LCID) Stock

Lucid Motors stock is falling after Cantor Fitzgerald analysts downgraded LCID shares and cut their price target following its Q3 earnings.

William White on InvestorPlace | November 8, 2023

Why Is Durect (DRRX) Stock Down 64% Today?

Durect stock is taking a beating on Wednesday as DRRX investors react to results from a Phase 2b clinical trial of larsucosterol.

William White on InvestorPlace | November 8, 2023

Why Is Sleep Number (SNBR) Stock Down 40% Today?

Sleep Number stock is falling on Wednesday as investors in SNBR react to the company missing EPS and revenue estimates for Q3.

William White on InvestorPlace | November 8, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.

William White on InvestorPlace | November 8, 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced topline results from its AHFIRM trial, a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of larsucosterol in 307 patients with severe alcohol-associated hepatitis (AH). Topline data from AHFIRM showed

Yahoo | November 7, 2023

These 2 ‘Strong Buy’ Penny Stocks Have Massive Upside Potential, Says Oppenheimer

Let’s talk about penny stocks. These are equities that trade for less than $5 per share, at the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – a low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among penny stocks and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig

Yahoo | October 19, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!